Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT

Journal of Nuclear Medicine

Volumn 48, Issue 4, 2007, Pages 538-546

  Leroy, Claire ^a,b   Comtat, Claude ^a   Trébossen, Régine ^a   Syrota, André ^a   Martinot, Jean Luc ^a,b   Ribeiro, Maria João ^a,b  

^a DIF   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Brain PET; Dopamine transporter; High spatial resolution; High resolution research tomography

Indexed keywords

CARBON 11; CARBON 11 PE2I; DOPAMINE TRANSPORTER; RADIOLIGAND; UNCLASSIFIED DRUG; CARBON; NORTROPANE DERIVATIVE;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; MESENCEPHALON; NEUROIMAGING; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; BRAIN; CHEMISTRY; CORPUS STRIATUM; IMAGE PROCESSING; INSTRUMENTATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; THREE DIMENSIONAL IMAGING; TIME;

ADULT; BRAIN; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MESENCEPHALON; MIDDLE AGED; NEURONS; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 34248571925     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.037283     Document Type: Article

References (40)

1. Sossi V, de Jong HWAM, Barker WC, et al. The second generation HRRT: a multi-centre scanner performance investigation. Nuclear Science Symposium Conference Record, 2005 IEEE, 23-29. 2005;4:2195-2199.
2. Herzog H, Tellmann L, Hocke C, et al. NEMA NU2-2001 guided performance evaluation of four Siemens ECAT PET scanners. IEEE Trans Nucl Sci. 2004;51:2662-2669.
3. Michel C, Schmand M, Liu X, et al. Reconstruction strategies for the HRRT. Nuclear Science Symposium Conference Record, 2000 IEEE. 2000;2:15/207-15/212.
4. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci. 1995;15:1714-1723.
5. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355-360.
6. 125I]PE2I. Neuroimage. 1999;9:108-116.
7. 125I]RTI-121 binding sites in human striatum and medial temporal lobe. J Pharmacol Exp Ther. 1995;274:1473-1483.
8. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-238.
9. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry. 2003;160:1699-1701.
10. 11C]cocaine images. Synapse. 1999;31:290-296.
11. 11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging. 2003;30:1220-1230.
12. Guilloteau D, Emond P, Baulieu JL, et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta- carbomethoxy-3beta-(4′-methylphenyl)nortropane (PE2I). Nucl Med Biol. 1998;25:331-337.
13. Kinahan PE, Rogers JG. Analytic three-dimensional image reconstruction using all detected events. IEEE Trans Nucl Sci. 1990;36:964-968.
14. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
15. 11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33:657-668.
16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
17. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2:189-210.
18. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage. 1999;9:545-553.
19. Nagano AS, Ito K, Kato T, et al. Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain: an approach using MRI-aided spatial normalization. Neuroimage. 2000;11:760-766.
20. 18F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med. 2004;45:1135-1145.
21. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10:36-43.
22. Heiss WD, Habedank B, Klein JC, et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med. 2004;45:1811-1815.
23. Bergstrom KA, Tupala E, Tiihonen J. Dopamine transporter in vitro binding and in vivo imaging in the brain. Pharmacol Toxicol. 2001;88:287-293.
24. 11C]MADAM: a test-retest reproducibility study. Synapse. 2006;60:256-263.
25. Volkow ND, Ding YS, Fowler JS, et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med. 1995;36:2162-2168.
26. Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 1986;126:175-176.
27. 3H]GBR-12935 in human putamen. Neurobiol Aging. 1989;10:661-664.
28. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology. 1997;48:969-977.
29. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol. 1999;409:25-37.
30. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47:1587-1594.
31. van Velden FHP, Kloet RW, de Jong HWAM, Lammertsma AA, Boellaard R. Quantitative experimental comparison of HRRT versus HR+ PET brain studies. IEEE Medical Imaging Conference: Conference Record 2006. 2006:M14-150.
32. Mazziotta JC, Phelps ME, Plummer D, Kuhl DE. Quantitation in positron emission computed tomography. 5. physical-anatomical effects. J Comput Assist Tomogr. 1981;5:734-743.
33. Sossi V, Camborde ML, Blinder S, et al. Dynamic imaging on the high resolution research tomograph (HRRT): non-human primate studies. 2005 IEEE Medical Imaging Conference: Conference Record. 2005:1981-1985.
34. de Jong HWAM, Boellaard R, Michel C, Lammertsam AA. Quantification of dynamic brain studies with the high resolution research tomograph. 2004 IEEE Medical Imaging Conference: Conference Record. 2004:3730-3732.
35. Sureau F, Comtat C, Reader AJ, et al. Improved clinical parametric imaging using list-mode reconstruction via resolution modeling. IEEE Medical Imaging Conference: Conference Record 2006. 2006:M15-6.
36. Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57:1293-1300.
37. Laakso A, Bergman J, Haaparanta M, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res. 2001;52:115-120.
38. Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580-586.
39. 18F]fluoro-L-dopa. J Cereb Blood Flow Metab. 2001;21:782-792.
40. Stoof JC, Winogrodzka A, van Muiswinkel FL, et al. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol. 1999;375:75-86.